Allen C Gao
University of California, Davis
H-index: 64
North America-United States
Top articles of Allen C Gao
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Novel dual inhibitors of AR/AR variants and AKR1C3: Preclinical activities for advanced prostate cancer therapy. | Allen Gao Shu Ning Cameron Armstrong Enming Xing Wei Lou | 2024/2/1 | |
MP60-17 THERAPEUTIC RESISTANCE MODELS AND TREATMENT SEQUENCING IN ADVANCED PROSTATE CANCER | The Journal of Urology | Zachary Schaaf Shu Ning Alan Lombard Chengfei Liu Wei Lou | 2024/5 |
IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer | Iscience | Amy R Leslie Shu Ning Cameron M Armstrong Leandro S D’Abronzo Masuda Sharifi | 2024/2/16 |
Dual targeting of HSP70 and AURKA improves treatment in neuroendocrine prostate cancer | Cancer Research | Pengfei Xu Joy C Yang Bo Chen Shu Ning Leyi Wang | 2024/3/22 |
MP05-11 PINK1 SIGNALING CONFERS OLAPARIB RESISTANCE BY ACTIVATING MITOCHONDRIAL FUNCTION IN ADVANCED PROSTATE CANCER CELLS | Journal of Urology | Allen Gao Zachary Schaaf Shu Ning Amy Leslie Masuda Sharifi | 2024/5/1 |
Genomic and evolutionary characterization of concurrent Intraductal carcinoma and adenocarcinoma of the prostate | Cancer Research | Jinge Zhao Nanwei Xu Sha Zhu Ling Nie Mengni Zhang | 2024/1/2 |
Stromal-derived MAOB promotes prostate cancer growth and progression | Science Advances | Tianjie Pu Jing Wang Jing Wei Alan Zeng Jinglong Zhang | 2024/2/9 |
The role of PLXND1 in lineage plasticity and progression to neuroendocrine prostate cancer | Cancer Research | Bo Chen Pengfei Xu Joy C Yang Shu Ning Leyi Wang | 2024/3/22 |
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer | Chengfei Liu Bo Chen Pengfei Xu Joy Yang Christopher Nip | 2024/3/27 | |
Bioengineered wnt5a therapeutics for advanced cancers | 2023/12/21 | ||
Dual androgen receptor/akr1c3 inhibitors | 2023/1/26 | ||
Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models | Pharmacological research | Pengfei Xu Joy C Yang Shu Ning Bo Chen Christopher Nip | 2023/3/1 |
Targeting noncanonical Wnt5a signaling suppresses the neural lineage network and overcomes enzalutamide resistance in advanced prostate cancer | Cancer Research | Shu Ning Wei Lou Chengfei Liu Joy C Yang Alan P Lombard | 2023/4/4 |
Abstract B076: IGFBP3 promotes resistance to olaparib via modulating EGFR signaling in advanced prostate cancer | Cancer Research | Amy R Leslie Allen C Gao Alan P Lombard Shu Ning | 2023/6/2 |
MP20-04 ARHGEF2 REGULATES LINEAGE PLASTICITY PROMOTING NEUROENDOCRINE DIFFERENTIATION AND TREATMENT RESISTANCE IN … | The Journal of Urology | Shu Ning Wei Lou Alan Lombard Masuda Sharifi Zachary Schaaf | 2023/4 |
Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer | Cancers | Zachary A Schaaf Shu Ning Amy R Leslie Masuda Sharifi Xianrui Han | 2023/11/3 |
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer | Oncogene | Joy C Yang Pengfei Xu Shu Ning Logan J Wasielewski Hans Adomat | 2023/2/24 |
PD04-09 COMBINATION TREATMENT WITH HSP70/STUB1 MODULATOR AND ENZALUTAMIDE YIELDS SYNERGISTIC ACTIVITY IN ADVANCED PROSTATE CANCER | The Journal of Urology | Pengfei Xu Joy C Yang Bo Chen Christopher Nip Shu Ning | 2023/4 |
PD16-02 CONCURRENT TARGETING AR/AR VARIANTS AND AKR1C3 FOR ADVANCED PROSTATE CANCER THERAPY | The Journal of Urology | Cameron Armstrong Shu Ning Wei Lou Christopher Evans Pui-Kai Li | 2023/4 |
Abstract B023: Targeting noncanonical Wnt5a signaling suppresses the neural lineage network and overcomes enzalutamide resistance in advanced prostate cancer | Cancer Research | Shu Ning Wei Lou Chengfei Liu Alan Paul Lombard Leandro S D' Abronzo | 2023/6/2 |
